Aptevo Therapeutics Inc. (APVO)
2025-06-30 | ||||
|---|---|---|---|---|
| Other income, net | 22 | |||
| Research and development | 3,328 | |||
| General and administrative | 2,898 | |||
| Loss from operations | -6,226 | |||
| Net loss | -6,204 | |||
| Basic net loss per share | -8.4 | |||
| Diluted net loss per share | -8.4 | |||
| Weighted average number of shares outstanding, basic, total | 738,149 | |||
| Weighted average number of shares outstanding, diluted, total | 738,149 | |||